Genentech

AntlerA Therapies is a regenerative medicine startup that is working on protein therapeutics that modulate developmental signaling pathways while also mobilizing tissue stem cell activity to enable endogenous tissue repair. They generated powerful antibody-like molecules (ANTs) that activate certain Frizzed receptor complexes using their unique protein engineering platform.

The 15 White Coats is a dynamic non-profit organization whose aim is to improve diversity in the medical sector by giving scholarships, mentorship, and support to underrepresented students pursuing medical degrees.

Yale Cancer Center is a cancer treatment center that provides prevention, detection, diagnosis, and treatment for cancer. They provide treatments for patient care,oncology, and hematology.

Adaptimmune Therapeutics, established in 2008, is a UK-based clinical-stage biopharmaceutical company specializing in novel cell therapies for solid tumor patients. Its core technology, the Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform, enables the identification of cancer targets and the development of affinity-enhanced T-cell receptors. Adaptimmune's pipeline includes several SPEAR T-cell therapies in phase I clinical trials, targeting various solid tumors such as urothelial, melanoma, and non-small cell lung cancer. The company has strategic collaborations with GSK, Noile-Immune Biotech, and Universal Cells, Inc. to advance its T-cell therapies.

Jecure Therapeutics, Inc. is a biotechnology company based in San Diego, California, established in 2015. The company specializes in developing small-molecule therapeutics aimed at treating non-alcoholic steatohepatitis (NASH) and liver fibrosis. Jecure Therapeutics focuses on innovative drug discovery programs that target serious inflammatory diseases. Its therapeutic approach involves blocking inflammasome activation and disrupting the sterile inflammation loop that leads to hepatocellular injury and cell death. The company utilizes advanced methodologies, including SiRNA-based murine models for target identification and validation, as well as a unique NASH model for in vivo screening, enabling the identification of drug candidates that can intervene throughout the disease process. As of 2018, Jecure Therapeutics operates as a subsidiary of Genentech, Inc.

Seragon Pharmaceuticals, Inc., based in Irvine, California, is a research-focused biopharmaceutical company dedicated to enhancing human and animal health through innovative scientific advancements. The company specializes in the development of orally active selective estrogen receptor degraders (SERDs), particularly targeting metastatic breast cancer. Its lead drug candidate, ARN-810, is currently under evaluation for the treatment of estrogen receptor-positive breast cancer. By leveraging cutting-edge research in metabolism, gene therapy, and bioinformatics, Seragon Pharmaceuticals aims to facilitate access to significant medical breakthroughs, encompassing both clinical applications and consumer products.

RQx Pharmaceuticals, Inc., a biopharmaceutical company, develops broad spectrum antibiotics. The company was founded in 2010 and is based in La Jolla, California.

Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapeutics for unmet medical needs in cancer treatment. The company specializes in the field of epigenetics, aiming to address cancers associated with abnormal gene expression and drug resistance. Its lead product candidates include CPI-0610, which is undergoing Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, currently in Phase Ib/II trials for metastatic castration-resistant prostate cancer in conjunction with androgen receptor signaling inhibitors. Additionally, Constellation is developing CPI-0209, which is in the Phase I dose escalation stage of a Phase I/II trial aimed at treating solid tumors. Founded in 2008, the company was previously known as Epigenetix, Inc. before rebranding to its current name in March 2008.

Curis, Inc. is a biotechnology company focused on the discovery and development of innovative drug candidates for the treatment of various human cancers. Headquartered in Lexington, Massachusetts, Curis is engaged in advancing its clinical-stage drug candidates, which include CA-4948, an oral small molecule currently in Phase I trials for non-Hodgkin lymphomas and acute myeloid leukemia, as well as monoclonal antibody CI-8993 and the oral dual inhibitor Fimepinostat for specific cancer types. The company's pipeline also features CA-170, aimed at advanced solid tumors and lymphomas, and CA-327, a pre-investigational drug candidate. Curis collaborates with notable organizations such as F. Hoffmann-La Roche and Genentech for the development of Erivedge, a treatment for advanced basal cell carcinoma, and partners with Aurigene Discovery Technologies and DarwinHealth to enhance its capabilities in immuno-oncology and precision oncology. Founded in 2000, Curis is committed to leveraging its expertise in signaling pathways to create targeted therapies for cancer treatment.

Curis, Inc. is a biotechnology company focused on the discovery and development of innovative drug candidates for the treatment of various human cancers. Headquartered in Lexington, Massachusetts, Curis is engaged in advancing its clinical-stage drug candidates, which include CA-4948, an oral small molecule currently in Phase I trials for non-Hodgkin lymphomas and acute myeloid leukemia, as well as monoclonal antibody CI-8993 and the oral dual inhibitor Fimepinostat for specific cancer types. The company's pipeline also features CA-170, aimed at advanced solid tumors and lymphomas, and CA-327, a pre-investigational drug candidate. Curis collaborates with notable organizations such as F. Hoffmann-La Roche and Genentech for the development of Erivedge, a treatment for advanced basal cell carcinoma, and partners with Aurigene Discovery Technologies and DarwinHealth to enhance its capabilities in immuno-oncology and precision oncology. Founded in 2000, Curis is committed to leveraging its expertise in signaling pathways to create targeted therapies for cancer treatment.

23andMe, Inc. is a consumer genetics and research company headquartered in Sunnyvale, California, founded in 2006. It specializes in providing direct-to-consumer personal genome services through home-based saliva collection kits. The company offers a range of services, including Health + Ancestry, which provides insights into ancestry, traits, and health, and Ancestry + Traits, which details ancestry breakdown and various trait reports. 23andMe aims to help individuals understand their genetic makeup, enabling users to explore their ancestry, genealogy, and inherited traits. Additionally, the company markets its services to researchers and scientists, offering categorized and searchable genetic data. With a focus on consumer and research services, 23andMe is positioned within the rapidly growing biotech and healthcare sectors, contributing to the understanding of genetics and its implications for health.

Proacta Inc. is a private, clinical-stage, biopharmaceutical company headquartered in San Diego, California. They are focused on addressing unmet needs in the field of cancer with the development of hypoxia-activated prodrugs that target cancer cells. Proacta was founded on intellectual property generated in New Zealand at the University of Auckland and in the United States at Stanford University. Proacta's patent family covers a series of hypoxia-activated prodrugs designed to treat cancer. Expansion of this portfolio is supported by ongoing research at The University of Auckland. PR610 is the lead compound from their pipeline of pro-drugs based on hypoxia-activated tyrosine-kinase inhibitors. These pro-drugs selectively release active tyrosine-kinase inhibitors within the low-oxygen (hypoxic) environment found in many solid tumors. By shifting the release of active drug away from normal tissues and into cancer tissues, these drugs are predicted to be more effective and less toxic than currently available therapies. To date, Proacta has raised $43 million in two private financings. Investors include Alta Partners, Clarus Ventures, Delphi Ventures, Endeavour Capital (New Zealand), GBS Venture Partners (Australia), Genentech, No 8 Ventures (New Zealand) and Roche.

Tanox, Inc. is a a biotechnology company, engages in the discovery and development of therapeutic monoclonal antibodies.

Tolerx, Inc. develops novel therapies focusing on modulating T-cell activities for treating autoimmune diseases, diabetes, and cancer. The company's products include otelixizumab, a targeted T-cell immunomodulator for treating type 1 diabetes; MTRX1011A, an anti-CD4 antibody for treating autoimmune indications; and TRX518 and TRX385, pre-clinical candidates that focuses on optimizing immune responses for treating cancer and chronic viral diseases. Tolerx, Inc., formerly known as TolerRx, Inc., was founded in 2000 and is based in Cambridge, Massachusetts.

HistoRx is developing theranostic solutions to towards individualized patient care. HistoRx's proprietary technology delivers objective and reproducible multiparametric analysis of proteins in tissue, providing insights into cancer treatment.

GlobeImmune, Inc. is a biopharmaceutical company based in Louisville, Colorado, specializing in the development of therapeutic products for cancer and infectious diseases utilizing its proprietary Tarmogen platform. Founded in 1995 as Ceres Pharmaceuticals, the company focuses on creating targeted molecular immunotherapies. Its product pipeline includes GS-4774, currently in Phase 2 trials for chronic hepatitis B infection, and GI-6301, aimed at cancers expressing the brachyury protein. Additionally, GlobeImmune is advancing GI-6207 for medullary thyroid cancer and GI-4000 for resected pancreatic cancer, with multiple Phase 2 clinical trials for various other cancers, including non-small cell lung cancer and colorectal cancer. The company is also developing several candidates targeting infectious diseases, including GI-19000 for tuberculosis, GI-2010 for HIV, and GI-18000 for hepatitis D, which are in preclinical stages. GlobeImmune has established strategic collaborations with notable organizations, enhancing its research and development efforts.

Kereos, Inc. is a biopharmaceutical company based in St. Louis, Missouri, specializing in the development of nanoscale drug delivery technologies and molecular imaging agents aimed at the detection and treatment of cancer and cardiovascular diseases. Founded in 1999, Kereos focuses on targeted delivery systems that enhance the effectiveness of therapeutic compounds, including existing drugs and novel candidates, particularly those that are too toxic or fragile for conventional delivery methods. The company's product portfolio includes KER-1001 and KER-1002, both cancer therapeutics utilizing natural products with demonstrated anti-tumor efficacy, and KER-1003, which targets angiogenesis. Additionally, Kereos offers diagnostic applications, such as KER 0001, an imaging platform for detecting angiogenesis. The company is also engaged in developing partnerships with pharmaceutical and imaging firms to advance its molecular imaging systems and cardiovascular disease MRI agents, thereby broadening its impact in the healthcare sector.

Tolerx, Inc. develops novel therapies focusing on modulating T-cell activities for treating autoimmune diseases, diabetes, and cancer. The company's products include otelixizumab, a targeted T-cell immunomodulator for treating type 1 diabetes; MTRX1011A, an anti-CD4 antibody for treating autoimmune indications; and TRX518 and TRX385, pre-clinical candidates that focuses on optimizing immune responses for treating cancer and chronic viral diseases. Tolerx, Inc., formerly known as TolerRx, Inc., was founded in 2000 and is based in Cambridge, Massachusetts.

Cellective Therapeutics is a biopharmaceutical company that engages in B Cell research for cancer and autoimmune diseases. Cellective focuses on monoclonal antibodies, which, with the company's technology, can be developed so specifically that they block the root causes of autoimmunity without interfering with the body's normal response to infections.

Tercica Inc., a biotechnology company, engages in the development and commercialization of therapeutics for the treatment of endocrine and metabolic diseases. Its products include Increlex, an rDNA origin injection for the long-term treatment of children with short stature due to severe primary IGFD; and Somatuline Depot, a lanreotide injection for the treatment of adults with acromegaly. Tercica Inc. has strategic partnerships with Genentech and Ipsen SA. The company was founded in 2002 and is based in Brisbane, California. As of October 16, 2008, Tercica Inc. operates as a subsidiary of Ipsen S.A.